Discover
DYAI
Dyadic International, Inc.
1.02
2 x 0.71
2 x 1.19
bid
ask
+
0.12
13.84%
2 @ 04:00 PM
0.96 -0.06 (5.83%)
| Ytd | 8.51% | |
| 1y | 5.15% |
0.90
day range
1.03
0.65
52 week range
1.35
| Open | 0.93 | Prev Close | 0.90 | Low | 0.90 | High | 1.03 | Mkt Cap | 37.17M |
| Vol | 308.33K | Avg Vol | 263.79K | EPS | -0.21 | P/E | N/A | Forward P/E | -5.59 |
| Beta | 0.72 | Short Ratio | 6.73 | Inst. Own | 16.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 0.77 | 200-d Avg | 0.89 | 1yr Est | 7.50 |
DYAI News
benzinga.com
Dyadic Announces Japan Patent Office Allowance Of Claims Covering Its Proprietary Thermothelomyces H
The Japan Patent Office allowed claims covering novel aspects of Dyadic’s proprietary Thermothelomyc
globenewswire.com
Dyadic Expands IP Protection and Business Development Activities in Japan
JUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic”
benzinga.com
Dyadic Highlights Increasing Interest In Proprietary C1 Protein Production Platform As Global Infect
Dyadic International, Inc. (NASDAQ:DYAI), d/b/a Dyadic Applied BioSolutions ("Dyadic" or the
benzinga.com
U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Re
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/